Display options
Cite
Cunningham JL, Virhammar J, Rönnberg B, et al. Anti-SARS-CoV2 antibody responses in serum and cerebrospinal fluid of COVID-19 patients with neurological symptoms. J Infect Dis. 2021;doi: 10.1093/infdis/jiab153.
Cunningham, J. L., Virhammar, J., Rönnberg, B., Castro Dopico, X., Kolstad, L., Albinsson, B., Kumlien, E., Nääs, A., Klang, A., Westman, G., Zetterberg, H., Frithiof, R., Lundkvist, �. �., Karlsson Hedestam, G. B., & Rostami, E. (2021). Anti-SARS-CoV2 antibody responses in serum and cerebrospinal fluid of COVID-19 patients with neurological symptoms. The Journal of infectious diseases, . https://doi.org/10.1093/infdis/jiab153
Cunningham, Janet L, et al. "Anti-SARS-CoV2 antibody responses in serum and cerebrospinal fluid of COVID-19 patients with neurological symptoms." The Journal of infectious diseases vol. (2021). doi: https://doi.org/10.1093/infdis/jiab153
Cunningham JL, Virhammar J, Rönnberg B, Castro Dopico X, Kolstad L, Albinsson B, Kumlien E, Nääs A, Klang A, Westman G, Zetterberg H, Frithiof R, Lundkvist Å, Karlsson Hedestam GB, Rostami E. Anti-SARS-CoV2 antibody responses in serum and cerebrospinal fluid of COVID-19 patients with neurological symptoms. J Infect Dis. 2021 Mar 21; doi: 10.1093/infdis/jiab153. Epub 2021 Mar 21. PMID: 33744954; PMCID: PMC8083780.
Copy Download .nbib Format: NLM
Share it on

J Infect Dis. 2021 Mar 21; doi: 10.1093/infdis/jiab153. Epub 2021 Mar 21.

Anti-SARS-CoV2 antibody responses in serum and cerebrospinal fluid of COVID-19 patients with neurological symptoms.

The Journal of infectious diseases

Janet L Cunningham, Johan Virhammar, Bengt Rönnberg, Xaquin Castro Dopico, Linda Kolstad, Bo Albinsson, Eva Kumlien, Anja Nääs, Andrea Klang, Gabriel Westman, Henrik Zetterberg, Robert Frithiof, Åke Lundkvist, Gunilla B Karlsson Hedestam, Elham Rostami

Affiliations

  1. Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden.
  2. Department of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden.
  3. Laboratory of Clinical Microbiology at Uppsala University Hospital, Uppsala, Sweden.
  4. Department of Medical Biochemistry and Microbiology, Zoonosis Science Center, Uppsala University, Uppsala, Sweden.
  5. Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
  6. Department of Medical Sciences, Section of Infectious Diseases, Uppsala University, Uppsala, Sweden.
  7. Department of Neuroscience, Rehabilitation Medicine, Uppsala University, Uppsala, Sweden.
  8. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  9. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  10. Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, United Kingdom.
  11. Department of Surgical Sciences, Anaesthesiology and Intensive Care, Uppsala University, Uppsala, Sweden.
  12. Department of Neuroscience, Neurosurgery, Uppsala University, Uppsala, Sweden.
  13. Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.

PMID: 33744954 PMCID: PMC8083780 DOI: 10.1093/infdis/jiab153

Abstract

Antibody responses to SARS-CoV-2 in serum and CSF from 16 COVID-19 patients with neurological symptoms were assessed using two independent methods. IgG specific for the virus spike protein was found in 81% of cases in serum and in 56% in CSF. SARS-CoV-2 IgG in CSF was observed in two cases with negative serology. Levels of IgG in both serum and CSF were associated with disease severity (p<0.05). All patients with elevated markers of CNS damage in CSF also had CSF antibodies (p=0.002), and CSF antibodies had the highest predictive value for neuronal damage markers of all tested clinical variables.

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Keywords: COVID-19; CSF; IgG; SARS-CoV-2; neurological symptoms; serology

Publication Types